Posted by Michael Wonder on 06 Oct 2021
Acer Therapeutics and Relief Therapeutics announce FDA acceptance for filing of new drug application for ACER-001 to treat urea cycle disorders
6 October 2021 - FDA sets PDUFA target action date of June 5, 2022.
Acer Therapeutics and its collaboration partner, Relief Therapeutics today announced that the U.S. FDA has accepted for filing the new drug application for ACER-001 (sodium phenylbutyrate) for the treatment of patients with urea cycle disorders.
